Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

Susanne Rauch, Karen Gooch, Yper Hall, Francisco J. Salguero, Mike J. Dennis, Fergus V. Gleeson, Debbie Harris, Catherine Ho, Holly E. Humphries, Stephanie Longet, Didier Ngabo, Jemma Paterson, Emma L. Rayner, Kathryn A. Ryan, Sally Sharpe, Robert J. Watson, Stefan O. Mueller, Benjamin Petsch, Miles W. Carroll
doi: https://doi.org/10.1101/2020.12.23.424138
Susanne Rauch
1CureVac AG Tuebingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: susanne.rauch@curevac.com
Karen Gooch
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yper Hall
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco J. Salguero
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike J. Dennis
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fergus V. Gleeson
3Department of Oncology, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debbie Harris
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Ho
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly E. Humphries
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Longet
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Ngabo
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jemma Paterson
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma L. Rayner
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn A. Ryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Sharpe
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Watson
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan O. Mueller
1CureVac AG Tuebingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Petsch
1CureVac AG Tuebingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles W. Carroll
2Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic necessitates the fast development of vaccines to meet a worldwide need. mRNA-based vaccines are the most promising technology for rapid and safe SARS-CoV-2 vaccine development and production. We have designed CVnCoV, a lipid-nanoparticle (LNP) encapsulated, sequence optimised mRNA-based SARS-CoV-2 vaccine that encodes for full length, pre-fusion stabilised Spike protein. Unlike other mRNA-based approaches, CVnCoV exclusively consists of non-chemically modified nucleotides and can be applied at comparatively low doses. Here we demonstrate that CVnCoV induces robust humoral and cellular responses in non-human primates (NHPs). Animals vaccinated with 8 μg of CVnCoV were protected from challenge infection with SARS-CoV-2. Comprehensive analyses of pathological changes in challenged animals via lung histopathology and Computed Tomography (CT) scans gave no indication of enhanced disease upon CVnCoV vaccination. These results demonstrate safety, immunogenicity, and protective efficacy of CVnCoV in NHPs that extend our previously published preclinical data and provide strong support for further clinical testing in ongoing phase 2b/3 efficacy studies.

Competing Interest Statement

S.R., B.P., and S.O.M. are employees of CureVac AG, Tuebingen Germany, a publically listed company developing RNA-based vaccines and immunotherapeutics. All authors may hold shares or stock options in the company. S.R. and B.P. inventors on several patents on mRNA vaccination and use thereof.

Footnotes

  • ↵# joint first author

  • ↵+ joint last author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 23, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Susanne Rauch, Karen Gooch, Yper Hall, Francisco J. Salguero, Mike J. Dennis, Fergus V. Gleeson, Debbie Harris, Catherine Ho, Holly E. Humphries, Stephanie Longet, Didier Ngabo, Jemma Paterson, Emma L. Rayner, Kathryn A. Ryan, Sally Sharpe, Robert J. Watson, Stefan O. Mueller, Benjamin Petsch, Miles W. Carroll
bioRxiv 2020.12.23.424138; doi: https://doi.org/10.1101/2020.12.23.424138
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Susanne Rauch, Karen Gooch, Yper Hall, Francisco J. Salguero, Mike J. Dennis, Fergus V. Gleeson, Debbie Harris, Catherine Ho, Holly E. Humphries, Stephanie Longet, Didier Ngabo, Jemma Paterson, Emma L. Rayner, Kathryn A. Ryan, Sally Sharpe, Robert J. Watson, Stefan O. Mueller, Benjamin Petsch, Miles W. Carroll
bioRxiv 2020.12.23.424138; doi: https://doi.org/10.1101/2020.12.23.424138

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4119)
  • Biochemistry (8828)
  • Bioengineering (6531)
  • Bioinformatics (23484)
  • Biophysics (11804)
  • Cancer Biology (9222)
  • Cell Biology (13336)
  • Clinical Trials (138)
  • Developmental Biology (7442)
  • Ecology (11424)
  • Epidemiology (2066)
  • Evolutionary Biology (15173)
  • Genetics (10452)
  • Genomics (14056)
  • Immunology (9187)
  • Microbiology (22198)
  • Molecular Biology (8823)
  • Neuroscience (47621)
  • Paleontology (351)
  • Pathology (1431)
  • Pharmacology and Toxicology (2493)
  • Physiology (3736)
  • Plant Biology (8090)
  • Scientific Communication and Education (1438)
  • Synthetic Biology (2224)
  • Systems Biology (6042)
  • Zoology (1254)